1-8 of 8
Zhi-xiang Shen, MD
Close
Sort by
Journal Articles

Frontline Nilotinib Results In Superior Rates Of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTchina 12-Month Primary Analysis

Xiaojun Huang, Jianxiang Wang, MD, Michele Baccarani, MD, Svetlana Jevtic, Christine-Elke Ortmann, Ye Yuan, Hans D. Menssen, MD, PhD, Giuseppe Saglio, Zhi-Xiang Shen, MD
Journal: Blood
Blood (2013) 122 (21): 1497.
https://doi.org/10.1182/blood.V122.21.1497.1497
Published: 2013
Journal Articles

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Jong Wook Lee, MD, PhD, Sung-Soo Yoon, MD, PhD, Zhi Xiang Shen, MD, Arnold Ganser, MD, Hui-Chi Hsu, MD, Ali El-Ali, MD, Dany Habr, MD, Bernard Roubert, PhD, John B. Porter, MD, on behalf of the EPIC study investigators
Journal: Blood
Blood (2011) 118 (21): 1344.
https://doi.org/10.1182/blood.V118.21.1344.1344
Published: 2011
Journal Articles

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).

Bing Chen, Xiang Wang, Ying Yao, Yong-Mei Zhu, Hai-Yan He, Xiao-Xing Jiang, Ji-Fang Zhou, Hai-Min Chen, Qi Cao, Guang Yang, Chun-Lei Jiang, Xiang-Qin Weng, Xu-Xi Zhang, Bo Jiao, Wei Li Zhao, MD, PhD, Jun-Min Li, Yu Chen, Shu-Min Xiong, Zhi-Xiang Shen, MD, Long-Jun Gu, MD, Hui Jiang, Jian-Qing Mi, Zhu Chen, Sai-Juan Chen, PhD
Journal: Blood
Blood (2009) 114 (22): 4718.
https://doi.org/10.1182/blood.V114.22.4718.4718
Published: 2009
Journal Articles

Long-Term Outcome of Imatinib Treatment in Chronic Myeloid Leukemia (CML) Patients in Shanghai: An International Patient Assistance Programs (GIPAP) Analysis.

Ai-hua Wang, Li Zhou, Yu Zheng, Jun-min Li, Zhi-Xiang Shen, MD, Jiong Hu, MD
Journal: Blood
Blood (2009) 114 (22): 4275.
https://doi.org/10.1182/blood.V114.22.4275.4275
Published: 2009
Journal Articles

Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib.

Jorge Cortes, MD, Hagop M Kantarjian, Dong- Wook Kim, MD, PhD, H. Jean Khoury, MD, FACP, Anna G. Turkina, MD, Zhi-Xiang Shen, MD, Tim H Brummendorf, MD, Mammen Chandy, MD, Steven Arkin, MD, Carlo Gambacorti-Passerini, MD
Journal: Blood
Blood (2008) 112 (11): 1098.
https://doi.org/10.1182/blood.V112.11.1098.1098
Published: 2008
Journal Articles

A Retrospective Study of Introferon-Alpha Treatment on Chinese Patients with Chronic Myeloid Leukemia

Hua Yan, Zhi-Xiang Shen, MD
Journal: Blood
Blood (2008) 112 (11): 4287.
https://doi.org/10.1182/blood.V112.11.4287.4287
Published: 2008
Journal Articles

A Multicentre, Randomized Study of FLAG Treatment in China(CHORT).

Hua Yan, Zhi-Xiang Shen, MD, Jianxiang Wang
Journal: Blood
Blood (2008) 112 (11): 948.
https://doi.org/10.1182/blood.V112.11.948.948
Published: 2008
Journal Articles

Bortezomib (Velcade™) Observational Study in China - Efficacy and Safety of Bortezomib Based Regimen in 223 Relapsed or Refractory Multiple Myeloma Patients.

Zhi-xiang Shen, MD
Journal: Blood
Blood (2007) 110 (11): 4833.
https://doi.org/10.1182/blood.V110.11.4833.4833
Published: 2007